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Autophagy in the heart is enhanced and
independent of disease progression in
mus musculus dystrophinopathy models
HR Spaulding1 , C Ballmann2, JC Quindry3 , MB Hudson4
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Abstract
Background: Duchenne muscular dystrophy is a muscle wasting disease caused by dystrophin gene mutations resulting
in dysfunctional dystrophin protein. Autophagy, a proteolytic process, is impaired in dystrophic skeletal muscle though
little is known about the effect of dystrophin deficiency on autophagy in cardiac muscle. We hypothesized that with
disease progression autophagy would become increasingly dysfunctional based upon indirect autophagic markers.
Methods: Markers of autophagy were measured by western blot in 7-week-old and 17-month-old control (C57) and
dystrophic (mdx) hearts.
Results: Counter to our hypothesis, markers of autophagy were similar between groups. Given these surprising results,
two independent experiments were conducted using 14-month-old mdx mice or 10-month-old mdx/Utrn mice, a
more severe model of Duchenne muscular dystrophy. Data from these animals suggest increased autophagosome
degradation.
Conclusion: Together these data suggest that autophagy is not impaired in the dystrophic myocardium as it is in
dystrophic skeletal muscle and that disease progression and related injury is independent of autophagic dysfunction.
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Introduction
Duchenne muscular dystrophy (DMD) is a muscle
wasting disease caused by the absence of functional
dystrophin protein. Dystrophin anchors the
dystrophin-associated glycoprotein complex (DGC),
which connects the extracellular matrix to the actin
cytoskeleton. This sarcolemmal architecture is neces-
sary for the DGC to function as a conduit of force
transduction, to provide stability to the sarcolemma,
and participate in intracellular signaling.1 In addition
to sarcolemmal instability,2 dystrophin deficiency
results in secondary cellular dysfunctions3–9 and ulti-
mately leads to loss of motor function, respiratory fail-
ure, and cardiac failure.
Autophagy functions as a homeostatic mechanism,
in which lysosomes degrade autophagosomal
cargo.10,11 Upon stimulation of autophagy, nucleation
of a phagophore begins and matures to become an
autophagosome, which packages tagged proteins,
organelles, and other cellular components.
Autophagosomes then fuse with lysosomes creating
an autophagolysosome, in which the autophagosomal
cargo is degraded. We recently demonstrated that in
dystrophic skeletal muscle degradation of autophago-
somes is impaired due, at least in part, to lysosomal
insufficiency.12 In other investigations, rapamycin was
used to inhibit mTOR in the mdx model, which
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increased autophagic flux and partially corrected
disease-related losses in skeletal and cardiac muscle
function.13,14 That stimulation of autophagy in the dys-
trophic myocardium preserved function suggests that
autophagy is impaired by dystrophin deficiency.
Other models of cardiac injury have shown that dys-
functional autophagy contributes to disease-related
injury,15–17 although in limb-girdle muscular dystrophy
dysfunctional autophagy was not apparent.18
Importantly, the extent to which autophagy changes
with progressive cardiac injury in DMD is unknown.
Consequently, the purpose of this investigation was to
determine the extent to which degradation of autopha-
gosomes is altered by disease progression in dystrophic
cardiac muscle. We hypothesized that degradation of
autophagosomes would become increasingly dysfunc-
tional with disease progression.
Methods
Animal treatment
All procedures were approved by the Institutional
Animal Care and Use Committees at Iowa State
University or Auburn University. In Experiment 1,
7 wk and 17mo C57 (7 wk n¼ 5; 17mo n¼ 3) and
mdx (7 wk n¼ 8; 17mo n¼ 8) male mice were sedated
with tribromoethanol (0.15ml/g) and sacrificed by
cervical dislocation. In an independent experiment
(Experiment 2), 14mo C57 and mdx mice (n¼ 7 per
group) were sedated with isoflurane and sacrificed by
cardiac excision. Before eight weeks of age, cardiac
function has been found to be normal in mdx mice
but progresses to cardiomyopathy by 10months of
age19; therefore, 7 wk old mice were used to model
early disease progression and 14–17mo mice were
used to model late disease progression. In Experiment
3, 10mo male C57 and dystrophin deficient mice hetero-
zygous for a utrophin mutation (mdx/Utrn) (n¼ 8 per
group) were treated as in Experiment 2. As these mice
also suffer from decreased utrophin abundance, they have
a more severe pathology compared to age-matched mdx
mice. Excised hearts from all mice were frozen and stored
at 80C for subsequent analyses. Previously published
data from this animal cohort include a detailed histopath-
ological examination of hearts for the C57, mdx, and
mdx/Utrn mice.20,21 Data regarding skeletal muscle
from these mice have also been previously published,22,23
including the effect of disease progression on markers of
autophagy.12
Biochemistry
Protein from hearts was isolated and subjected to west-
ern blotting as previously described.12,20,23 Briefly,
cardiac muscle was powdered using a dry ice-chilled
metal mortar and pestle, protein extracted and concen-
tration measured, and loaded onto a 4–20% gradient
gel (Lonza). After separation and transfer, membranes
were stained with Ponceau stain to verify equal load-
ing, blocked in 5% milk made in Tris buffered saline
with 0.2% Tween20 (TBST) and incubated in primary
antibody overnight at 4C. Membranes were washed
and secondary antibodies were applied for 1 h at
room temperature. Dilutions of primary and secondary
antibodies were used as follows from Cell Signaling
Technology Inc. (Danvers, MA, USA), unless other-
wise noted: AMP-activated protein kinase (AMPK)
(product no. 5832, Primary (P) 1:1000 5% milk in
TBST, Secondary (S) 1:2000 2.5% milk in TBST),
phosphorylated (p) AMPK (T172) (product no. 2535,
P 1:1000 in TBST, S 1:2000 5% milk in TBST), Unc-51
Like Autophagy Activating Kinase 1 (ULK) (product
no. 8054, P 1:500 in TBST, S 1:500 in TBST), p-ULK1
(S555) (product no. 5869, P 1:500 1% milk in TBST,
S 1:500 in TBST), phosphoinositide 3-kinases (PI3K)
Class III (product no. 3358, P 1:1000 5% milk in
TBST, S 1:1000 5% milk in TBST), beclin 1 (product
no. 3495, P 1:750 5% milk in TBST, S 1:1000 in TBST),
p-beclin 1 (S93) (product no. 14717, P 1:500 1% milk in
TBST, S 1:500 in TBST), autophagy-related protein
(ATG) 5 (product no. 9980, P 1:1000 5% milk in
TBST, S 1:2000 5% milk in TBST), ATG5/12 (product
no. 4180, P 1:1000 1% milk in TBST, S 1:2000 5% milk
in TBST), ATG7 (product no. 2631, P 1:1000 in TBST,
S1:2000 in TBST), light chain 3 (LC3) (product no.
12741, P 1:500 5% milk in TBST, S 1:2000 5% milk
in TBST), sequestosome 1 (SQSTM1, p62) (Abcam,
Cambridge, UK) (product no. EPR4844, P 1:500 5%
milk in TBST, S 1:1000 5% milk in TBST). Species
specific secondary antibodies were obtained from
Cell Signaling Technology Inc. (product no. 7074S,
Danvers, MA, USA). ClarityTM (BioRad, Hercules,
CA, USA) enhanced chemiluminescence was applied
to each membrane for approximately 7min, and then
films were developed in a dark room to visualize pro-
tein bands. Protein bands were quantified using
Carestream densitometry software (Carestream
Health, Inc., New Haven, CT).
qPCR
Quantitative PCR was used to evaluate Spstm1 (p62)
transcript abundance. RNA was extracted from snap
frozen, powdered tissue using TriZol (15596018,
ThermoScientific) and RNeasy purification kit
(Qiagen), then cDNA was reverse transcribed using
QuantiTect Reverse Transcriptase Kit (205310,
Qiagen). Manufacturers’ protocols were followed
except for use of random hexamers (51-0118-01, IDT
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Premade Primers) instead of the RT primer mix pro-
vided (Qiagen). Sqsmt1 (p62) was evaluated (Forward
– 50tgtggtgggaactcgctataa-30, Reverse – 50-cagcggctat-
gagagaagctat-30) and normalized to 18s (Forward –
50-ctctagataacctcgggccg-30, Reverse – 50-gtcgggagtggg-
taatttgc-30).
Statistics
In Experiment 1, a two-way analysis of variance was
used to compare differences between 7 wk and 17mo
C57 and mdx mice groups with age and disease status
as main effects followed by a Newman–Keul post
hoc test when indicated. In Experiments 2 and 3,
a Student’s t-test was used to compare differences
between groups. Significance was established at
P< 0.05, a priori.
Results
Experiment 1: 7 wk and 17mo C57 and mdx mice
In skeletal muscle from these mice we previously
reported impaired degradation of autophagosomes
due, at least in part, to a lysosomal insufficiency.12
To assess the effects of disease severity on markers of
autophagy in dystrophic hearts, markers of activation,
autophagosome formation, and autophagosome degra-
dation were measured. Relative protein abundance and
phosphorylation of upstream autophagy activator
AMPK at threonine 172 (p-AMPK (T172)) was similar
between groups as was the ratio of phosphorylated to
total AMPK protein (Figure 1). ULK1 protein abun-
dance was decreased as a function of dystrophin
deficiency compared to healthy hearts (Figure 2).
Phosphorylation of ULK1 at serine 555 (p-ULK1
(S555)) was similar between groups as was p-ULK1
(S555)/ULK1 ratio. After activation by ULK1, beclin
1 binds with PI3K class III to initiate phagophore for-
mation.24 Relative protein abundance of PI3K class
III, beclin 1, and p-beclin 1 (S93)/beclin 1 ratio were
similar between groups, though relative abundance of
p-beclin 1 increased as a function of age.
The maturation of a phagophore to an autophago-
some is regulated by ATG proteins. Specifically, ATG5
and 12 form a complex that ultimately binds with
ATG16L. ATG5 protein abundance was similar
between groups and abundance of the ATG5/12 com-
plex increased as a function of age but was independent
of disease status (Figure 3). The lipidation of LC3I to
LC3II suggests movement toward the formation of
mature autophagosomes, thus the ratio of LC3II/I
was used as a marker for autophagic maturation.
LC3I, LC3II, and LC3II/I were similar between
healthy and diseased groups, though LC3II protein
abundance and LC3II/I ratio increased as a function
of age (Figure 4). Lastly, protein abundance of p62, an
inverse correlate of autophagic degradation,25 was sim-
ilar between groups. Further, p62 transcript expression
was measured and was also similar between groups.
Experiment 2: 14mo C57 and mdx mice
We previously reported increased histological damage
and declining cardiac function in dystrophic hearts20 as
well as substantial impairments to limb and diaphrag-
matic function in these animals.22,23 Biochemical find-
ings from 14mo hearts largely recapitulated findings
from Experiment 1. Protein markers of autophagosome
maturation, ATG5 and 7, were similar between groups.
LC3I was also similar between groups; however,
LC3II, a marker of autophagosome abundance, was
decreased by 56% in mdx mice compared to C57 rais-
ing the possibility of increased degradation of
Figure 1. Activation of autophagy. AMPK is similar between
C57 and mdx mice at both 7 wk and 17mo of age. Significance
was established at p< 0.05. White bars – C57 7 wk (n¼ 4–5),
gray bars – mdx 7 wk (n¼ 7–8), white bars with black hatching –
C57 17mo (n¼ 3), black bars – mdx 17mo (n¼ 8).
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autophagosomes (Table 1). p62 protein abundance was
similar between groups.
Experiment 3: 10mo C57 and mdx/Utrn mice
A common criticism of the mdx model is its mild phe-
notype. While our investigation deliberately used mice
early in disease progression (7 wk) and with evident
cardiomyopathy (14 and 17mo), we also assessed
autophagy in a more severe disease model that is dys-
trophin deficient and heterozygous for a utrophin
mutation (mdx/Utrn). We previously found that
hearts from 10-month-old mdx/Utrn mice are severely
damaged and demonstrate cardiac function decline
compared to age-matched C57 mice.21 Notably,
beclin 1 protein abundance was decreased by 10% in
mdx/Utrn compared to C57 mice but ATG5 and
ATG7 were similar between groups (Figure 5).
Relative protein abundance of LC3I was similar
between groups but LC3II and LC3II/I were signifi-
cantly reduced by 50% suggestive of increased degra-
dation of autophagosomes. Lastly, p62 protein
abundance was similar between groups.
Discussion
DMD is caused by the absence of dystrophin protein
and collapse of the DGC. Dystrophic muscle cells are
susceptible to contraction-induced injury resulting in
secondary effects such as sarcolemma injury and cell
degeneration.26 The application of advanced respirato-
ry support therapies now prolongs life in those with
DMD to the extent that cardiomyopathy is an emer-
gent threat facing these patients. Recent evidence indi-
cates that several cardioprotective drugs27 and
nutraceuticals.20,21,28 attenuate the severity of cardio-
myopathy. Recently, autophagy has been identified as
a target for pharmacological manipulation as autoph-
agy is blunted in dystrophic skeletal muscle serving to
limit removal of protein aggregates and damaged
organelles.12,14 Pleiotropic therapeutics, such as
mTOR inhibitors, which may, among other effects,
activate autophagy, have successfully decreased disease
severity in dystrophic skeletal and cardiac muscle13,14;
however, the role of autophagy in progressive cardio-
myopathy is unknown. We hypothesized that with
advancing cardiac injury autophagy would exhibit
markers of progressive dysfunction.
Figure 2. Initiation of autophagy. Markers of autophagic initiation were similar between all groups. Significance was established at
p< 0.05. White bars – C57 7 wk (n¼ 4–5), gray bars – mdx 7 wk (n¼ 7–8), white bars with black hatching – C57 17mo (n¼ 3), black
bars – mdx 17mo (n¼ 8). # indicates significant main effect of age, † indicates significant main effect of disease.
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On the whole, markers of autophagy were similar
between healthy and diseased hearts at 7 wk and
17mo of age, suggesting that autophagy is independent
of disease-related injury to the myocardium. As these
results were quite unexpected and there were numerical
changes in several key variables, particularly with
advanced disease, we carried out two additional confir-
matory experiments. In the first confirmatory experi-
ment using 14mo mice, LC3II protein abundance
decreased and p62 was similar in diseased hearts com-
pared to healthy, raising the possibility that degrada-
tion of autophagosomes is enhanced in dystrophic
cardiac muscle as autophagosomes are being degraded
rapidly resulting in decreased LC3II. Further
supporting this notion, LC3II abundance was
decreased without alteration in p62 in 10mo mdx/
Utrn mice compared to healthy. Given findings
from Experiments 2 and 3, data from Experiment 1,
in which LC3II and LC3II/I ratio were numerically
decreased without a change in p62, could be supportive
of increased degradation of autophagosomes, particu-
larly in aged mice. Collectively these findings are inter-
esting and raise novel insights into the nuanced role of
autophagy and disease progression in dystro-
phic hearts.
Based on our preliminary interpretation of these
findings, the reader should be aware that conclusions
are tempered to match study design limitations.
Figure 3. Autophagosome formation. ATG proteins involved in autophagosome formation were similar between all groups,
suggesting no alteration in autophagosome formation in dystrophic cardiac muscle regardless of age. Significance was established at
p< 0.05. White bars – C57 7 wk (n¼ 4–5), gray bars – mdx 7 wk (n¼ 7–8), white bars with black hatching – C57 17mo (n¼ 3), black
bars – mdx 17mo (n¼ 8). # indicates significant main effect of age.
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Specifically, the current approach relied upon archived
samples, and as such, measures of autophagic flux were
not immediately feasible. An alternative interpretation
of these findings does not exclude the possibility that
autophagy is impaired in dystrophic hearts. If autoph-
agy were impaired, a reduction in LC3II could reflect
decreased autophagosome formation and reduced effi-
ciency of autophagosome degradation as suggested by
similar p62. However, published findings likely do not
support the notion of decreased autophagic flux in that
a well-designed study focused on dystrophic hearts
clearly delineated that LC3II increased following
Figure 4. Autophagic degradation. (a,b) Markers of autophagosome degradation were similar between mdx and age-matched
controls. (c) Transcript abundance of Sqstm1, which encodes p62, was similar between all groups. Significance was established at
p< 0.05. White bars – C57 7 wk (n¼ 4–5), gray bars – mdx 7 wk (n¼ 7–8), white bars with black hatching – C57 17mo (n¼ 3), black
bars – mdx 17mo (n¼ 8). # indicates significant main effect of age.
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inhibition of autophagic degradation with chloroquine,
indicative of increased flux.29 In combination with out-
comes in the current investigation, these findings sug-
gest an increased flux accompanies disease progression.
Indeed, careful scrutiny of work by Kang et al. indi-
cates that autophagy increased following isolation of
cardiomyocytes, which the authors attributed to cellu-
lar stress caused specifically by isolation.29 An impor-
tant extension of this point is that despite increased
autophagy as a result of dystrophinopathy, cells were
able to further increase autophagy suggesting it could
be responsive to therapeutics intended to stimulate
autophagy. In support, stimulation of autophagy via
inhibition of mTOR was cardioprotective in 18mo
mdx mice.13
Our first experiment also provides a limited oppor-
tunity to consider the effect of aging on markers of
autophagy in healthy hearts. Here, we found that
p-beclin and the ATG12/5 complex were increased as
a function of age suggesting increased activation of
autophagy. We also discovered increased LC3II and
LC3II/I without a corresponding change in p62.
Accumulation of LC3II can be due to either an increase
in formation of autophagosomes, or a failure to
degrade autophagosomes, or a combination of the
two. As LC3II increased without a corresponding
increase in p62 it is suggestive of increased degradation
of autophagosomes in hearts from 17mo mice com-
pared to 7 wk old mice. Such findings are consistent
with aging studies using pathway biomarkers of mice of
similar age30; however, in older mice autophagic dys-
function is apparent.31–34
In total, and counter to our hypothesis, indices of
autophagic dysregulation were not evident in dystro-
phic hearts examined in these experiments. We inter-
pret this finding to be particularly important in that the
emergent understanding of autophagy in various car-
diomyopathies, including dystrophic heart failure,
is more nuanced and contextual than initially
thought.16,17 Indeed, findings from the current investi-
gation include hearts from several mouse cohorts that
Table 1. Autophagy in 14mo C57 and mdx mice.
C57 mdx p-Value
beclin 1 1.00 0.04 0.95 0.11 0.71
ATG5 1.00 0.03 1.00 0.07 0.98
ATG7 1.00 0.03 1.02 0.07 0.81
LC3I 1.00 0.04 0.97 0.13 0.83
LC3II 1.00 0.20 0.44 0.08a 0.02
LC3II/I 1.00 0.22 0.59 0.20 0.19
p62 1.00 0.02 0.99 0.03 0.76
Note: Markers of autophagy were largely similar except LC3II, a marker
of autophagosome maturation, which was significantly decreased.
Mean SEM.
aSignificantly different from C57 controls (p< 0.05). C57 14mo (n¼ 7)
and mdx 14mo (n¼ 7).
Figure 5. Autophagy in 10mo C57 and mdx/Utrn mice. Markers of autophagosome maturation (LC3II and LC3II/I) were signif-
icantly decreased while p62, a marker of autophagosome degradation, was similar. Significance was established at p< 0.05. White bars
– C57 10mo (n¼ 8) and black bars – mdx/Utrn 10mo (n¼ 8). * indicates significantly different from C57 controls.
Spaulding et al. 7
exhibited significant evidence of histochemical and
physiological pathology.20,21 As such, these initial
experiments to probe autophagy in dystrophic hearts
suggest that despite disease progression, markers of
autophagic activation and degradation appear to be
independent of disease-related cardiomyopathy in the
dystrophic myocardium. Moreover, our collective evi-
dence is interpreted within the current literature,29
which suggests autophagy is enhanced in dystrophin-
deficient hearts. Given the pathologic intracellular
environment of a dystrophin-deficient fiber and that
(nonspecific) autophagy activators provided therapeu-
tic benefits,13 cellular activators of autophagy may rep-
resent druggable targets leading to cardioprotection.
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